Alpha emitter radium-223 and survival in metastatic prostate cancer - sprookjes - yvandenbroek - TriplyDB

Alpha emitter radium-223 and survival in metastatic prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

http://www.wikidata.org/entity/Q29617472

about

Immunobiology and immunotherapy in genitourinary malignancies Galeterone for the treatment of advanced prostate cancer: the evidence to date From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastases Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?A Perspective of Immunotherapy for Prostate Cancer Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases Targeted Radionuclide Therapy: Practical Applications and Future Prospects Molecular signaling involving intrinsically disordered proteins in prostate cancer Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS)Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer Prostate cancer is not breast cancer Targeted Radionuclide Therapy of Human Tumors Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science Sequence of treatment in locally advanced and metastatic renal cell carcinoma Diagnostic Performance of Diffusion-weighted Magnetic Resonance Imaging in Bone Malignancy: Evidence From a Meta-Analysis Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer Minimally invasive local treatments for bone and pulmonary metastases Immunotherapy for prostate cancer: recent developments and future challenges Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223 Current clinical challenges in prostate cancer Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer Well-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastases Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy Targeting the adaptive molecular landscape of castration-resistant prostate cancer What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold Radioisotopes in management of metastatic prostate cancer Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Androgen deprivation therapy as backbone therapy in the management of prostate cancer Epigenetic modulators as therapeutic targets in prostate cancer Immunotherapy in metastatic prostate cancer Radionuclides

P2860

Q26738668-F47FE672-BB1B-4180-8E99-23517712151B Q26739887-5964138D-2E4B-4429-BB40-69B347E7CE5E Q26740064-B707F62D-30FE-4E4C-AFC7-BE062B287C0A Q26740601-70BB9CA7-DD96-4E9E-B64C-F92FF823D832 Q26741277-2B37308B-41BF-4581-8B26-75BFC71D3A4C Q26744355-8AF1363E-3C66-452C-89FF-FA9BF23DE4BB Q26745926-EDC36BE7-E25F-4700-8B86-F4FCB7D4F45E Q26747089-86875B07-8A9B-4D7D-832F-9290EB43D14E Q26747566-AD65944C-FE6E-4497-85CA-AAA8C8AC876E Q26747699-92E2CBDA-027F-4037-B08F-8BC3CC308370 Q26747782-E87A0B57-0714-4425-BA70-5B37C103C2A0 Q26751354-EF225079-99B8-4855-A31D-4B7069884004 Q26771267-DA5796DB-93E8-40EA-943B-FC03A521A99E Q26772883-E7FB5B5F-E0A8-46ED-82E3-DADB988A3BF2 Q26773653-3F263650-CBFC-42EF-80E0-E0913C48724B Q26777520-8BB2352E-9592-44E9-B0B5-8B2B2A461C11 Q26785658-4C9EF1C6-F8CC-4B38-A437-F40E529E5288 Q26786543-65D6C44A-480A-4A9B-8C53-941C8FFFEAFD Q26796568-035B6976-AC3E-4BF3-A5ED-9D0909ED8F10 Q26823733-2EFD75BA-A6FF-452F-BE0B-BB09F2F7AB6F Q26849767-8DCCA7C2-6075-4743-A735-78CB57A09225 Q26852388-0B7849FA-67B3-4B1E-9411-CEC212042871 Q26852544-AB19408A-4989-4682-B4E7-6FB3A80CE201 Q26861575-A6571340-A3CB-4BB3-8EA1-F9F58B175F4D Q26866036-D0294F5C-9214-40B6-8834-3C9C7FC163F0 Q27002342-355B78D2-06AB-46A8-B2EB-AB0DEAE1A7D1 Q27002591-CA627649-51B9-413A-AA45-5839D890B4AA Q27004566-00C1180A-087A-4CE7-98D5-F6D1C05D7732 Q27011642-AC0AE298-8D95-4DAD-95B7-21473934ADB4 Q27021268-6825FBF0-39FD-41C9-981E-05E1585F0422 Q27022715-13131A41-CE63-452D-B0E7-856CB5B39E5C Q27022821-C970658A-122A-41D0-BB57-04C1BE6167B9 Q28066240-4339E886-BC28-41E9-AC24-6CBC388AA63E Q28066293-ECC4D70D-D494-4F53-A0D6-40C212608314 Q28068134-D6986D44-A063-4613-B567-D5F709CBB59E Q28068956-089FE9E5-77F1-4DF6-86BA-AC5CB0542176 Q28071795-1225B925-BD47-474B-B688-26B2B63F0578 Q28071912-D8E875B0-D242-44F8-820D-5BDB1C37F522 Q28072081-9390D3DD-A9ED-4AA9-980E-DA929FA37E4A Q28072149-CFDAC36E-2800-47E3-8A73-2DAC605DE101

P2860

Alpha emitter radium-223 and survival in metastatic prostate cancer

http://www.wikidata.org/entity/Q29617472

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Alpha emitter radium-223 and survival in metastatic prostate cancer

@ast

Alpha emitter radium-223 and survival in metastatic prostate cancer

@en

type

label

Alpha emitter radium-223 and survival in metastatic prostate cancer

@ast

Alpha emitter radium-223 and survival in metastatic prostate cancer

@en

prefLabel

Alpha emitter radium-223 and survival in metastatic prostate cancer

@ast

Alpha emitter radium-223 and survival in metastatic prostate cancer

@en

P1433

Q29617472-BAAC1BFE-786F-4259-AEFF-C17B70EBFE75

P1476

Q29617472-D0456F11-B003-455C-948C-16BEC25C18A4

P2093

Q29617472-1C9CDAC9-EEC6-4C8C-8556-04540A936414

Q29617472-28D55839-C2D2-4AB8-B7C4-B7A2CEC64057

Q29617472-29E6C564-4E31-4E34-8411-91575DDB58D7

Q29617472-3940D034-9AA5-49BC-86EC-80A09AFCEFAB

Q29617472-46D10218-311B-4B01-B2AA-E0317198759B

Q29617472-47A93264-7E91-4AF0-85F2-2A49622C2798

Q29617472-4EB374DE-9F83-462B-B1F0-B40DF2C33A41

Q29617472-5FEFCE67-36C9-4D8C-9A28-20981961AC90

Q29617472-60E7F861-5209-4C34-86E6-A6B466FF08DE

Q29617472-70B173CC-4CF7-4145-A064-5385C1B0FC4C

P304

Q29617472-09AA9E13-B393-44E7-AAFE-04D4FC969D77

P31

Q29617472-8993147B-6184-4384-A41F-ACC603E5447A

P3181

Q29617472-AED1BAC6-82FD-4B16-8BBE-7C95488EE0FF

P356

Q29617472-7635A4FD-46FB-4B57-AD9B-7FB50B1919A3

P407

Q29617472-E2F511B0-C40E-4737-9015-DD0BBD21E112

P433

Q29617472-ABF49B96-8FE2-4276-B461-0F7705F32CF9

P478

Q29617472-4D11C932-C72D-4415-AAB7-0189D10F16CF

P50

Q29617472-48B805CD-319D-4CD4-96D5-53B3607BBC19

Q29617472-4A9265D1-2543-400D-A5E1-9C049B9B2328

Q29617472-A068E346-082A-4596-BEC5-FD6A0D45CCB7

Q29617472-A8D7F3F5-3BA1-41EF-9C5E-37373FC9085C

P577

Q29617472-8CD4CCE6-E79B-4B37-A303-BA841CCEA23B

P698

Q29617472-E2538A15-9982-4061-A8D6-9523370755EE

P921

Q29617472-DFFA52BF-5D4A-4BA8-9F53-1C3781DA56F3

P3181

P356

P1433

The New England Journal of Medicine

P1476

Alpha emitter radium-223 and survival in metastatic prostate cancer

@en

P2093

A Chodacki

http://www.w3.org/2001/XMLSchema#string

A Solberg

http://www.w3.org/2001/XMLSchema#string

A Widmark

http://www.w3.org/2001/XMLSchema#string

ALSYMPCA Investigators

http://www.w3.org/2001/XMLSchema#string

C G O'Bryan-Tear

http://www.w3.org/2001/XMLSchema#string

C Parker

http://www.w3.org/2001/XMLSchema#string

D Bottomley

http://www.w3.org/2001/XMLSchema#string

D C Johannessen

http://www.w3.org/2001/XMLSchema#string

D Heinrich

http://www.w3.org/2001/XMLSchema#string

I Syndikus

http://www.w3.org/2001/XMLSchema#string

P304

213-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

598588

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1213755

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Sophie D. Fosså

Marcos Francisco Dall'Oglio

Øyvind Sverre Bruland

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23863050

http://www.w3.org/2001/XMLSchema#string

P921

radium ra-223 dichloride